Patents Examined by Lisa V. Cook
  • Patent number: 12007391
    Abstract: The present invention relates to methods for predicting a risk of a subject for Type 1 diabetes (T1D) on the basis of expression levels of protein markers in a sample obtained from the subject. The present invention also relates to in vitro kits for use in said methods.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: June 11, 2024
    Assignee: TURUN YLIOPISTO
    Inventors: Robert Moulder, Santosh Bhosale, David Goodlett, Harri Lähdesmäki, Olli Simell, Riitta Lahesmaa
  • Patent number: 11981959
    Abstract: Heritable pathogenic variants in the mismatch repair (MMR) pathway, also known as Lynch Syndrome (LS), can lead to the development of colon cancer and other cancers. Following mismatch, a complex of proteins consisting of MLH1, MSH2, MSH6 and PMS2 translocate into the nucleus to signal recruitment of repair mechanisms. Flow cytometry-based, functional variant assays (FVAs), were developed to determine whether variants in these MMR repair genes and/or other related genes would augment the nuclear translocation of MLH1 and MSH2 and downstream nuclear phosphorylation of ATM and ATR in response to DNA mismatches. Each assay distinguished pathogenic variants in MMR repair genes (MLH1, MSH2, PMS2 and MSH6) from benign controls. The combination of multiple assays provided robust separation between heterozygous pathogenic variant carriers and benign controls.
    Type: Grant
    Filed: May 19, 2022
    Date of Patent: May 14, 2024
    Inventors: Harry Ostrer, Johnny C. Loke, Ishraq Alim
  • Patent number: 11977077
    Abstract: The present invention relates to pancreatic cancers and the use of biomarkers in biological samples for the diagnosis of such conditions, in particular pancreatic ductal adenocarcinoma. The biomarker panel comprises LYVE1, REG1 and TFF1. Methods of treatment are also provided, as well as kits useful in the diagnosis and treatment of pancreatic ductal adenocarcinoma. The present invention is particularly useful in detecting early-stage PDAC.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: May 7, 2024
    Assignee: Queen Mary University of London
    Inventors: Tatjana Crnogorac-Jurcevic, Tomasz Radon
  • Patent number: 11977074
    Abstract: The invention relates to methods and products associated with in vivo enzyme profiling. In particular, biomarker nanoparticles capable of quantitatively detecting enzymatic activity in vivo are described. These nanoparticles can be used to detect in vivo enzyme activity. The invention also relates to products, kits, and databases for use in the methods of the invention.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: May 7, 2024
    Assignee: Massachusetts Institute of Technology
    Inventors: Sangeeta N. Bhatia, David K. Wood, Gabriel A. Kwong, Andrew David Warren, Kevin Y. Lin
  • Patent number: 11970680
    Abstract: The invention generally relates to a microfluidic platforms or “chips” for testing and understanding cancer, and, more specifically, for understanding the factors that contribute to cancer invading tissues and causing metastases. Tumor cells are grown on microfluidic devices with other non-cancerous tissues under conditions that simulate tumor invasion. The interaction with immune cells can be tested to inhibit this activity by linking a cancer chip to a lymph chip.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: April 30, 2024
    Assignee: EMULATE, Inc.
    Inventors: Geraldine A. Hamilton, Norman Wen, Catherine Karalis, Antonio Varone, Daniel Levner, Riccardo Barrile
  • Patent number: 11971410
    Abstract: Provided herein are methods for classifying how a subject having a cancer will respond to immunotherapeutic (IT) therapy based on the subject's immunosignature or frameshift signature. Also provided herein are methods for classifying a subject having a cancer as having a good prognosis or a poor prognosis based on the subject's immunosignature or frameshift signature.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: April 30, 2024
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventor: Stephen Johnston
  • Patent number: 11965887
    Abstract: A method of examining a possibility of a subject having pancreatic cancer, including measuring GPRC5C (G protein-coupled receptor family C group 5 member C) present in an exosome in a specimen collected from the subject.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: April 23, 2024
    Assignee: THEORIA Science Inc.
    Inventors: Takahiro Ochiya, Yusuke Yoshioka
  • Patent number: 11958912
    Abstract: Herein is reported a method for determining the binding interaction with a multimeric antigen of an antibody of the human IgG1 subclass that has at least two binding sites specifically binding to the antigen comprising the steps of 1) determining the binding affinity of the antibody for the multimeric antigen, and 2) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain of Porphyromonas gingivalis under conditions and for a time sufficient to cleave the antibody into Fabs and Fc-region, and determining the binding affinity of the Fabs of the antibody for the multimeric, whereby the binding affinity of the antibody to the multimeric antigen to be affinity-driven if the binding affinity determined in both steps are comparable and to be avidity-driven if the binding affinity determined in both steps are different.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: April 16, 2024
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Joerg Moelleken, Michael Molhoj, Christian Gassner, Manuel Endesfelder, Joerg-Thomas Regula
  • Patent number: 11933785
    Abstract: This invention provides minimally invasive methods, reagents, diagnostic and prognostic markers useful for staging, prognosis and surveillance of colorectal cancers, and therapeutic intervention in individuals with colorectal cancers, or individuals who may be susceptible to developing colorectal cancers.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: March 19, 2024
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Michael Richard Sussman, Melanie Mae Ivancic, Gregory D Kennedy, William Franklin Dove, Perry Joseph Pickhardt, Mark Reichelderfer
  • Patent number: 11933784
    Abstract: Disclosed are compositions and methods to detect proteins associated with Head and Neck Cancer, generally, or more particularly, biomarkers of Head and Neck Squamous Cell Carcinoma (HNSCC). Such markers may be useful to allow individuals susceptible to HNSCC to manage their lifestyle and/or medical treatment to avoid further progression of disease.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: March 19, 2024
    Assignee: Laboratory Corporation of America Holdings
    Inventor: Gerald J. Wallweber
  • Patent number: 11921116
    Abstract: The present disclosure relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. Accordingly, in certain non-limiting embodiments, the present disclosure provides for methods, compositions and kits for a companion diagnostic for CDK4 inhibitors, and in particular, for the use of the colocalization of Enigma and CDH18 biomarkers to foci within the cancer for determining whether the cancer can be successfully treated by CDK4 inhibition.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: March 5, 2024
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Mary Elizabeth Dooley, Marta Kovatcheva, Samuel Singer, William D. Tap, Aimee Crago, Andrew Koff
  • Patent number: 11906532
    Abstract: Quality control formulations that do not require human donor-derived blood components for use in testing the efficacy of viscoelastic analysis reagents, and methods for preparing these formulations, are described.
    Type: Grant
    Filed: March 24, 2022
    Date of Patent: February 20, 2024
    Assignee: Haemonetics Corporation
    Inventor: Xiaohua Qian
  • Patent number: 11892448
    Abstract: Herein is reported a method for the determination of the binding affinity of a binder and its ligand comprising the step of determining based on the result of an immunoassay the fraction of free binder in a sample comprising binder, ligand and binder-ligand-complexes for at least two different binder:ligand ratios in the sample, and if the determined fraction of free binder is not comparable for all used binder:ligand ratios then the binder:ligand ratio in the sample is lowered and the sample is re-analyzed by the same immunoassay, and calculating based on the fraction of free binder in the previous step the binding affinity for the binder to its ligand.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: February 6, 2024
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Uwe Dahl, Gregor Jordan, Roland Staack
  • Patent number: 11892454
    Abstract: The present invention pertains to a diagnostic and therapeutic method for assessing whether a patient is susceptible to the treatment of an ester-prodrug. The methods of the invention include the analysis of carboxyelesterase 2 (CES2)-expression in tumor samples as a predictive value for the assessment of treatment success with an ester-prodrug of a chemotherapeutic agent. Alternatively, the invention provides methods involving the analysis of the urinary ratio of the prodrug and the active therapeutic as another predictive value for assessing treatment susceptibility.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: February 6, 2024
    Assignee: CELLACT PHARMA GMBH
    Inventor: Nalan Utku
  • Patent number: 11885808
    Abstract: High levels of nuclear NMT1 are associated with longer relapse free survival in ER? positive breast cancer patients. Both low levels of cytosolic and nuclear NMT1 correlated to very poor clinical outcomes. NMT2 also plays an important function in breast cancer signalling, regulated through phosphorylation. For example, NMT2 phosphorylation status is a key element in the progression of ER+ breast cancer cells. Specifically, nuclear localization of NMT2 is associated with poor outcomes in breast cancer patients.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: January 30, 2024
    Assignee: Oneodrek Inc.
    Inventor: Anuraag Shrivastav
  • Patent number: 11874275
    Abstract: The present disclosure relates to the technical field of rapid detection of molecules, and specifically relates to a method for rapid fluorescent immunoassay (FIA) and chemiluminescent immunoassay (CLIA) based on electrokinetic acceleration. The method includes the following steps sequentially: S1. sample acceleration: applying an actuating signal to a chip on which a target molecule is dripped to obtain a chip binding to the target molecule, where the chip includes an electrode sheet and coating molecules is immobilized on the electrode sheet; and S2. secondary antibody acceleration: adding a secondary antibody for binding to the target molecule dropwise on the chip binding to the target molecule, and applying an actuating signal to the chip to obtain a chip binding to the secondary antibody. The method can effectively improve a rate of FIA and CLIA, and can speed up a detection process and meet the need for rapid point-of-care testing (POCT).
    Type: Grant
    Filed: June 5, 2023
    Date of Patent: January 16, 2024
    Assignee: FOSHAN MICROWONDERS BIOTECHNOLOGY CO., LTD.
    Inventors: Xiaozhu Liu, Hai Xu, Yanmin Li, Jun Li, Yong Hu, Li Tong, Jie Lin, Zhidong Zhang, Lihua Yang, Liang Ma, Zheng Zeng, Linggao Zeng, Li Chen, Shengxi Wu, Shenghui Qin
  • Patent number: 11874282
    Abstract: The present disclosure relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also disclosed are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present disclosure further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Finally, the present disclosure relates to a device or kit adapted to carry out the method of the present invention.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: January 16, 2024
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Martin Hund, Edelgard Anna Kaiser, Ursula-Henrike Wienhues-Thelen, Dirk Block, Johann Karl
  • Patent number: 11867691
    Abstract: An image processing device includes a determination unit configured to determine a type of autophagy induced in a cell, based on information indicative of autophagic activity in the cell present in a cell image in which the cell is image captured and based on information indicative of congestion of molecules in the cell present in the cell image.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: January 9, 2024
    Assignees: NIKON CORPORATION, THE UNIVERSITY OF TOKYO
    Inventors: Kenta Imai, Mamiko Masutani, Masayuki Murata, Fumi Kano, Yoshiyuki Noguchi
  • Patent number: 11859010
    Abstract: Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs). Also provided herein are methods of making and methods of use of these antibodies, AAs, bispecific antibodies, and BAAs.
    Type: Grant
    Filed: September 7, 2022
    Date of Patent: January 2, 2024
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Leila Marie Boustany, Sherry L. La Porte, Bryan A. Irving, Jeanne Grace Flandez
  • Patent number: 11828759
    Abstract: The present invention relates generally to a method of detecting a risk of the progression from a pre-invasive neoplasia of the glandular epithelium. More particularly, the present invention provides a method of detecting a risk of the progression from a pre-invasive breast neoplasia by screening for the level of expression of Stefin A in the myoepithelial cells. The method of the present invention is useful in a range of applications including, but not limited to, assessing a neoplastic condition, monitoring the progression of such a condition, predicting the likelihood of a subject progressing to a more advance disease state or informing decisions in relation to the design of treatment schedules.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: November 28, 2023
    Assignee: Peter MacCallum Cancer Institute
    Inventors: Belinda Sheree Parker, Hendrika Martha Duivenvoorden